Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Leukemia

• Publication date

  2009-07-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2009.134PMID 19587704
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frequency of pathological proteins (M-components) om 6,995 sera from an adult population.

  2009cited by this paper
• Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors.

  2009cited by this paper
• Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance

  2009cited by this paper
• Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

  2009cited by this paper
• A monoclonal gammopathy precedes multiple myeloma in most patients.

  2009cited by this paper
• Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma: a prospective study

  2009cited by this paper
• Familial myeloma and monoclonal gammopathy: A report of eight African American families

  2009cited by this paper
• Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

  2009cited by this paper
• The impact of race on outcomes of autologous transplantation in patients with multiple myeloma

  2008cited by this paper
• Familial myeloma.

  2008cited by this paper
• Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

  2008cited by this paper
• Familial myeloma.

  2008cited by this paper
• Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.

  2008cited by this paper
• Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

  2008cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.

  2007cited by this paper
• Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size.

  2007cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.

  2007cited by this paper
• Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

  2007cited by this paper
• Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels.

  2007cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance.

  2006cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance.

  2006cited by this paper
• Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population‐based case‐control study

  2006cited by this paper
• Dissecting racial and ethnic differences.

  2006cited by this paper
• Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• No Evidence for Anticipation in Lymphoproliferative Tumors in Population-Based Samples

  2005cited by this paper
• Phenotypic heterogeneity in multiple myeloma families.

  2005cited by this paper
• Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

  2005cited by this paper
• DISEQUILIBRIUM: ADVANCES, LIMITATIONS AND GUIDELINES

  2005cited by this paper
• Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

  2005cited by this paper
• Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families.

  2005cited by this paper
• Advances in biology of multiple myeloma: clinical applications.

  2004cited by this paper
• Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study

  2004cited by this paper
• Drug therapy: Multiple myeloma

  2004cited by this paper
• Myeloma and race: A review of the literature

  2003cited by this paper
• Re: familial multiple myeloma: a family study and review of the literature.

  2002cited by this paper
• Re: familial multiple myeloma: a family study and review of the literature.

  2002cited by this paper
• Multiple myeloma

  2001cited by this paper
• Incidence of hematological malignancies in Martinique, French West Indies, overrepresentation of multiple myeloma and adult T cell leukemia/lymphoma

  2001cited by this paper
• Familial multiple myeloma: a family study and review of the literature.

  2001cited by this paper
• Multiple myeloma and family history of cancer among blacks and whites in the U.S.

  1999cited by this paper
• National database of familial cancer in Sweden

  1998cited by this paper
• Waldenström's macroglobulinemia

  1998cited by this paper
• Cancer Incidence in Five Continents

  1997cited by this paper
• Multiple myeloma among Blacks and Whites in the United States: role of cigarettes and alcoholic beverages

  1997cited by this paper
• Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.

  1996cited by this paper
• Familiality of cancer in Utah.

  1994cited by this paper
• Incidence of Waldenström's macroglobulinemia.

  1993cited by this paper
• A Comparative Study of Monoclonal Gammopathies and Immunoglobulin Levels in Japanese and United States Elderly

  1993cited by this paper
• HLA and multiple myeloma among black and white men: evidence of a genetic association.

  1992cited by this paper
• Occurrence of monoclonal components in general practice: Clinical implications

  1992cited by this paper
• Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting.

  1990cited by this paper
• Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital.

  1987cited by this paper
• Prevalence of M-proteins in serum of hospitalized patients. Physicians' response to finding M-proteins in serum protein electrophoresis.

  1987cited by this paper
• Multiple myeloma and family history of cancer a case—control study

  1985cited by this paper
• Monoclonal gammopathies in the adult population of Finistère, France.

  1982cited by this paper
• Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

  1978cited by this paper
• The significance of monoclonal gammopathy in a normal population.

  1971cited by this paper
• Cancer Incidence in Five Continents

  1970cited by this paper
• Studies on conditions associated with disturbed gamma globulin formation (gammopathies).

  1960cited by this paper
• Multiple myeloma.

  1948cited by this paper

• Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen?

  2026cites this paper
• A Call for Compassion: How You Can Help Get Multiple Myeloma Added to the Social Security Administration's Compassionate Allowances List.

  2026cites this paper
• Pre-transplant Predictive Factors in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Using Defective Cure Models

  2025cites this paper
• Prevalence, detection, and clinical implications of BRAF V600E and NRAS Q61R mutations in multiple myeloma BM-FFPE tissues using digital droplet PCR

  2025cites this paper
• Opportunities to Avoid Invasive Cancer by Diagnosis and Interception of Preneoplastic Lesions and Cancer Risk Conditions.

  2025cites this paper
• Predicting the Progression from Asymptomatic to Symptomatic Multiple Myeloma and Stage Classification Using Gene Expression Data

  2025cites this paper
• Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma

  2025cites this paper
• Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure

  2025cites this paper
• Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis

  2025cites this paper
• Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study

  2025cites this paper
• Global Burden of Multiple Myeloma in Older Adults From 1990 to 2021 and Modelled Projection to 2050.

  2025cites this paper
• Significant Reduction in Peak Left Ventricular Global Longitudinal Strain in Multiple Myeloma Patients: A Pilot Random Awareness Analysis

  2025cites this paper
• Germline and somatic genetic effects on gene expression and outcome in patients with Multiple Myeloma

  2024cites this paper
• Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment

  2024cites this paper
• Risk stratification in multiple myeloma – A review and update

  2024cites this paper
• Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma

  2024cites this paper
• Effect of human bone marrow mesenchymal stem cell-derived microvesicles on the apoptosis of the multiple myeloma cell line U266

  2024cites this paper
• Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.

  2024cites this paper
• Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

  2024influential citation
• Germline predisposition in multiple myeloma

  2024cites this paper
• Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection.

  2024cites this paper
• An emergency medicine review: Multiple myeloma and its complications.

  2024cites this paper
• Transcriptome of bone marrow-Derived stem cells reveals new inflammatory mediators related to increased survival in patients with multiple myeloma.

  2024cites this paper
• Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy

  2023cites this paper
• Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS)

  2023cites this paper
• Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma.

  2023cites this paper
• Perspectives on the Treatment of Multiple Myeloma

  2023cites this paper
• Update on the outcome of M‐protein screening program of multiple myeloma in China: A 7‐year cohort study

  2023cites this paper
• Population screening for smoldering multiple myeloma reveals high prevalence

  2023cites this paper
• New Biological Therapies for Multiple Myeloma.

  2023cites this paper
• Genomic Profiling to Contextualize the Results of Intervention for High-Risk Smoldering Myeloma

  2023influential citation
• Utility of Serum and Urine Protein Electrophoresis in Evaluation of Chronic Kidney Disease Patients

  2022cites this paper
• Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

  2022influential citation
• Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

  2022cites this paper
• Expression levels and patterns of B‐cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent

  2022cites this paper
• Multiple myeloma etiology and treatment

  2022cites this paper
• Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China.

  2022cites this paper
• Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations.

  2022cites this paper
• Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling

  2022cites this paper
• Evaluation of mandibular bone changes in multiple myeloma patients on dental panoramic radiographs

  2022cites this paper
• Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma

  2022influential citation
• Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia

  2022cites this paper
• Multi‐trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance

  2022cites this paper
• Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives

  2022influential citation
• Prevalence of Race/Ethnicity Reporting in Light Chain (AL) Amyloidosis Clinical Research in the USA

  2022cites this paper
• Intramedullary nailing for pathological fractures of the proximal humerus caused by multiple myeloma: A case report and review of literature

  2022cites this paper
• Demographic differences among patients treated with chimeric antigen receptor T‐cell therapy in the United States

  2022cites this paper
• Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis

  2022cites this paper
• Multiple myeloma in Lebanon: Trend analysis, 10-year projections and comparisons to other countries.

  2022cites this paper
• Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka

  2022influential citation
• Clinical study of multiple myeloma and treatment responses in a tertiary care centre

  2021cites this paper
• Functional Precision Profiling: The Way Forward for Personalized Medicine

  2021cites this paper
• Hyperdiploid Multiple Myeloma with Novel Complex Structural Chromosome Abnormalities Associated with Poor Prognosis : A Rare Case Report

  2021cites this paper
• P-094: ABT-199 and epigenetic modifiers: promising novel combinations for the treatment of Multiple Myeloma

  2021cites this paper
• Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

  2021cites this paper
• Maternal ancestry and hematological cancer risk: case-control study in an Argentinean population.

  2021cites this paper
• Intramedullary Nailing for Pathological Fractures of the Proximal Humerus caused by Multiple Myeloma: A Case Report and Literature Review

  2021cites this paper
• World Journal of Clinical Cases

  2021cites this paper
• Epidemiology, Staging, and Management of Multiple Myeloma

  2021cites this paper
• Pathobiology, Epidemiology, and Diagnosis of Multiple Myeloma

  2021cites this paper
• Are African primary physicians suspicious enough? Challenges of multiple myeloma diagnosis in Africa

  2021influential citation
• Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples

  2021cites this paper
• Corrected estimated glomerular filtration rate is a predictor for survival in multiple myeloma patients

  2020cites this paper
• Second malignancies in multiple myeloma; emerging patterns and future directions.

  2020cites this paper
• Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

  2020influential citation
• The significance of prognostic profiling in the treatment of patients with multiple myeloma

  2020cites this paper
• Dissecting racial disparities in multiple myeloma

  2020cites this paper
• Ocular Adnexal Lymphoproliferative Disease

  2020cites this paper
• Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma

  2020cites this paper
• Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study

  2020cites this paper
• An atypical presentation of multiple myeloma in a young patient with pathological fracture

  2020cites this paper
• Diagnosis dan Terapi Terkini Multiple Myeloma

  2020cites this paper
• Proteomics and functional study reveal marginal zone B and B1 cell specific protein as a candidate marker of multiple myeloma.

  2020cites this paper
• Immunoglobulin M Paraproteinaemias

  2020cites this paper
• Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial‐ethnic group, United States 2003‐2016

  2020cites this paper
• Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients

  2020cites this paper
• Whole genome sequencing provides evidence of two biologically and clinically distinct entities of asymptomatic monoclonal gammopathies: progressive versus stable myeloma precursor condition

  2020cites this paper
• Serum metabolomic alterations in multiple myeloma revealed by targeted and untargeted metabolomics approaches: a pilot study

  2019cites this paper
• Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

  2019cites this paper
• IgA plasma cell neoplasms are characterized by poorer long-term survival and increased genomic complexity compared to IgG neoplasms.

  2019cites this paper
• Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

  2019cites this paper
• Minimal Residual Disease Assessment in Myeloma

  2019cites this paper
• Analyse transcriptomique des cellules stromales mésenchymateuses au cours du traitement du Myélome Multiple

  2019cites this paper
• Presentation and survival of multiple myeloma patients in Ghana: a review of 169 cases

  2019cites this paper
• An approach to the diagnosis and management of multiple myeloma

  2019cites this paper
• Racial disparities, cancer and response to oxidative stress.

  2019cites this paper
• Identifying monoclonal gammopathy of undetermined significance in electronic health data

  2019cites this paper
• Low knowledge and awareness of monoclonal gammopathy of undetermined significance (MGUS) among general practitioners

  2019cites this paper
• Treatment evolution and improved survival in multiple myeloma in Taiwan

  2019cites this paper
• Monoclonal gammopathy of undetermined significance.

  2019cites this paper
• Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.

  2019cites this paper
• Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution

  2019cites this paper
• Of ABCB 1 t-129 c pOlymOrphism and multiple myelOma risk in pOlish pOpulatiOn

  2019cites this paper
• Distribution of multiple myeloma in India: Heterogeneity in incidence across age, sex and geography.

  2019cites this paper
• Monoclonal gammopathy of undetermined significance as viewed by haematology healthcare professionals

  2018cites this paper
• Predictive factors of therapeutic response in multiple myeloma in the Cameroonian subject: A multicentric study in Yaoundé

  2018cites this paper
• Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies

  2018cites this paper
• Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

  2018influential citation
• An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring

  2018cites this paper
• Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

  2018cites this paper